Author

D. Sang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Adjuvant T-DM1 versus trastuzumab plus pertuzumab for residual disease after neoadjuvant dual HER2 blockade in HER2-positive early breast cancer: a multicenter real-world study

Despite the established benefit of adjuvant trastuzumab emtansine (T-DM1) over trastuzumab in HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant chemotherapy plus HER2-targeted therapy, comparison of efficacy between T-DM1 and dual HER2 blockade (trastuzumab plus pertuzumab, HP) remai...

Yue-Ran Jia, Shi-Hao Liang, Wei Wu et al. · BMC Cancer · 0 citations

#protein folding Open access Sep 2026

Plasma multi-omics reveals molecular remodeling and prognostic biomarkers in advanced breast cancer treated with trastuzumab deruxtecan

Paired plasma multi-omics revealed T-DXd-associated proteomic and metabolic remodeling and the molecular patterns and PFS-associated biomarkers are hypothesis-generating and require validation in larger independent cohorts.

D. Sang, Wen-Yu Yang, Jin-Song Liu et al. · Frontiers in Oncology · 0 citations